SynthesisThe Lancet. Global health2022
Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden.
Synthesis in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06833957 (PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa), which is not on this map. Cited by 133 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PReparing for OptimalPhase III/IV maTErnal Group B StreptococCal Vaccine Trials in Africa (PROTECT)
Who cites it
133 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Systematic Review and Meta-analysis of Group B Streptococcus Rectovaginal Colonization Rates and Serotype Distribution among Pregnant Women, Asia-Pacific Region, 2014-2025.Emerging infectious diseases · 2026Pooled it
- Prevalence of Group BMedical sciences (Basel, Switzerland) · 2026Pooled it
- Gestational diabetes as a risk factor for GBS maternal rectovaginal colonization: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2024Pooled it
- Research focus and emerging trends of the gut microbiome and infant: a bibliometric analysis from 2004 to 2024.Frontiers in microbiology · 2024Pooled it
- Clinical Characteristics and Treatment Strategies for Group B Streptococcus (GBS) Infection in Pediatrics: A Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.Nature medicine · 2026Trial
- A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals.The Journal of infectious diseases · 2025Trial
- Characterization of Resolved, Localized, and Progressing Infections at the Maternal-Fetal Interface in a Nonhuman Primate Model.bioRxiv : the preprint server for biology · 2026Article
- Time to rethink prevention of neonatal group B streptococcal disease.Seminars in immunopathology · 2026Review
- Preparing for Future Group BVaccines · 2026Article
- A Rapid Molecular Detection Method for Streptococcus agalactiae Based on Bacteriophage Lysin Lysis and Real-Time PCR.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A retrospective study of alternative antibiotics for prophylaxis of the Group B Streptococcus maternal-fetal disease.Infection · 2026Article
- Article
- Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.Nature communications · 2026Article
- Prevalence, Serotype Distribution, and Antimicrobial Resistance ofJournal of clinical medicine · 2026Article
- Article
- Home is where the host is: evolutionary history of geographic spread, host switching and adaptive genomic signatures in two generalist group BMicrobial genomics · 2026Article
- Group B Streptococcus antibiotics treatment during pregnancy and the risk of four neurodevelopmental outcomes in Swedish children.Scientific reports · 2026Article
- Bacterial targeting of the neutrophil inhibitory receptor LILRB3 to evade antibody immunity.Nature communications · 2026Article
- RodA promotes intestinal colonization by group BInfection and immunity · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
33 authors.
Funding
Abstract
backgroundGroup B streptococcus (GBS) colonisation during pregnancy can lead to invasive GBS disease (iGBS) in infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal infections, and prematurity. There are data gaps, notably regarding neurodevelopmental impairment (NDI), especially after iGBS sepsis, which have limited previous global estimates. In this study, we aimed to address this gap using newly available multicountry datasets.
methodsWe collated and meta-analysed summary data, primarily identified in a series of systematic reviews published in 2017 but also from recent studies on NDI and stillbirths, using Bayesian hierarchical models, and estimated the burden for 183 countries in 2020 regarding: maternal GBS colonisation, iGBS cases and deaths in infants younger than 3 months, children surviving iGBS affected by NDI, and maternal iGBS cases. We analysed the proportion of stillbirths with GBS and applied this to the UN-estimated stillbirth risk per country. Excess preterm births associated with maternal GBS colonisation were calculated using meta-analysis and national preterm birth rates.
findingsData from the seven systematic reviews, published in 2017, that informed the previous burden estimation (a total of 515 data points) were combined with new data (17 data points) from large multicountry studies on neurodevelopmental impairment (two studies) and stillbirths (one study). A posterior median of 19·7 million (95% posterior interval 17·9-21·9) pregnant women were estimated to have rectovaginal colonisation with GBS in 2020. 231 800 (114 100-455 000) early-onset and 162 200 (70 200-394 400) late-onset infant iGBS cases were estimated to have occurred. In an analysis assuming a higher case fatality rate in the absence of a skilled birth attendant, 91 900 (44 800-187 800) iGBS infant deaths were estimated; in an analysis without this assumption, 58 300 (26 500-125 800) infant deaths from iGBS were estimated. 37 100 children who recovered from iGBS (14 600-96 200) were predicted to develop moderate or severe NDI. 40 500 (21 500-66 200) maternal iGBS cases and 46 200 (20 300-111 300) GBS stillbirths were predicted in 2020. GBS colonisation was also estimated to be potentially associated with considerable numbers of preterm births.
interpretationOur analysis provides a comprehensive assessment of the pregnancy-related GBS burden. The Bayesian approach enabled coherent propagation of uncertainty, which is considerable, notably regarding GBS-associated preterm births. Our findings on both the acute and long-term consequences of iGBS have public health implications for understanding the value of investment in maternal GBS immunisation and other preventive strategies.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.